Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 9, 2003Insmed Incorporated to Present Positive Oncology Data On rhIGFBP-3 at the Annual Meeting of the American Association of Cancer Research
-
Jun 23, 2003Insmed Launches Pivotal Phase III Clinical Trial in GHIS; Data Analysis Planned for Early 2004
-
Jun 20, 2003Insmed Presents Positive Data on Lead Drug Candidate at Endocrine Society Annual Meeting; Study Shows Advantages of Company's rhIGF-I/rhIGFBP-3 In Treating Growth Disorder
-
Jun 20, 2003Insmed Receives European Orphan Drug Designation For rhIGF-I/rhIGFBP-3; Product Will Have 10 Years of Market Exclusivity in Treatment of Growth Disorder
-
Jun 19, 2003Insmed Announces Management Reorganization; Ronald D. Gunn Promoted to Executive VP; Lewis Stuart Departs as VP Commercial Development
-
Jun 18, 2003Insmed to Present Lead Drug Candidate at the Endocrine Society Annual Meeting
-
Jun 17, 2003Insmed Selected to Present to BIO 2003 Business Forum; Presentation to be Webcast Live
-
Jun 12, 2003Insmed to Report Positive Effects of rhIGF-I/rhIGFBP-3 In Adolescent Subjects with Type 1 Diabetes
-
Jun 2, 2003Insmed Presents Data To ASCO Highlighting Potential Benefit Of rhIGFBP-3 in Cancer; rhIGFBP-3 Shown to Enhance Chemotherapy in Models of Human Breast Cancer
-
May 29, 2003Insmed to Present Positive Cancer Data to ASCO
Your Privacy Choices